SCHEMBL7011897

SCHEMBL7011897

CCc1cc2cc(OC)ccn2c1C(=O)c1ccccc1-c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.45
TAS1R1 Q7RTX1 1/20 0.45
GAA P10253 2/20 0.44
KDM4E B2RXH2 1/20 0.44
BAZ2B Q9UIF8 1/20 0.43
BAZ2A Q9UIF9 1/20 0.43
POLB P06746 1/20 0.41
PLA2G2A P14555 2/20 0.41
PLA2G1B P04054 3/20 0.39
CYP2C8 P10632 1/20 0.39
TRPV1 Q8NER1 1/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38
SMARCA2 P51531 1/20 0.38
SMARCA4 P51532 1/20 0.38
BRD9 Q9H8M2 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7015571 0.82 GAA (0.42) TAS1R3TAS1R1GAAKDM4EBAZ2B
SCHEMBL7018295 0.78 PLA2G1B (0.48) BAZ2BBAZ2APLA2G2APLA2G1B
SCHEMBL7011415 0.71 LTA4H (0.41) BAZ2BBAZ2APLA2G1B
SCHEMBL7013840 0.71 PLA2G1B (0.47) PLA2G2APLA2G1B
SCHEMBL7014377 0.69 KDM2B (0.39) KDM4EMAPK1
SCHEMBL3890527 0.68 THRB (0.49) GAAPOLBSMN1; SMN2LMNAMAPK1
SCHEMBL8887143 0.68 GAA (0.59) TAS1R3TAS1R1GAAKDM4EPOLB
SCHEMBL28454034 0.68 BCAT2 (0.52) CNR1CNR2SMN1; SMN2LMNA
SCHEMBL8338154 0.67 SMN1; SMN2 (0.71) GAAKDM4EPOLBCYP2C8SMN1; SMN2
SCHEMBL3886748 0.67 SMN1; SMN2 (0.49) GAAKDM4EPOLBSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6645976-B1 Nonpancreatic secretory phospholipase (sPLA2) supressors such as 2-(3-Benzyl-8-hydroxy-2-ethylindolizin-1-yl)acetamide, administered to control release of fatty acid and prevent the arachidonic acid cascade; septic shock ELI LILLY AND COMPANY 2003-11-11 US disclosed
EP-0772596-B1 INDOLIZINE sPLA2 INHIBITORS LILLY CO ELI (US) 2003-10-01 EP disclosed
EP-0772596-A4 INDOLIZINE sPLA2 INHIBITORS LILLY CO ELI (US) 1999-01-13 EP disclosed
EP-0772596-A1 INDOLIZINE sPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 1997-05-14 EP disclosed
WO-1996003383-A1 INDOLIZINE sPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 1996-02-08 WO disclosed